Results 61 to 70 of about 410,320 (404)

Heart failure with preserved ejection fraction.

Journal of geriatric cardiology : JGC, 2013
Progressive aging of the population and prolongation of life expectancy have led to the rising prevalence of heart failure (HF). Despite the improvements in medical therapy, the mortality rate of this condition has remained unacceptably high, becoming the primary cause of death in the elderly population.
Whalley, Gillian, Rigolli, Marzia
openaire   +4 more sources

Heart Failure With Preserved Ejection Fraction in the Young [PDF]

Circulation, 2018
Background: Heart failure with preserved ejection fraction (HFpEF), traditionally considered a disease of the elderly, may also affect younger patients. However, little is known about HFpEF in the young. Methods: We prospectively enrolled 1203 patients with HFpEF (left ventricular ...
Lieng H. Ling, Michael R. Zile, Michael R. Zile, Carolyn S.P. Lam, Calambur Narasimhan, Michael R. MacDonald, Wataru Shimizu, Chung-Lieh Hung, A. Mark Richards, A. Mark Richards, Jasper Tromp, Wan Ting Tay, Inder S. Anand, Jonathan Yap, John J.V. McMurray, Tiew-Hwa Katherine Teng, Tze Pin Ng   +16 more
openaire   +6 more sources

Similarity-based prediction of Ejection Fraction in Heart Failure Patients [PDF]

arXiv, 2022
Biomedical research is increasingly employing real world evidence (RWE) to foster discoveries of novel clinical phenotypes and to better characterize long term effect of medical treatments. However, due to limitations inherent in the collection process, RWE often lacks key features of patients, particularly when these features cannot be directly ...
arxiv  

Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial

Circulation, 2021
Supplemental Digital Content is available in the text. Background: Patients with heart failure with preserved ejection fraction have significant impairment in health-related quality of life.
J. Butler, G. Filippatos, T. Jamal Siddiqi, M. Brueckmann, M. Böhm, V. Chopra, João Pedro Ferreira, J. Januzzi, S. Kaul, I. Piña, P. Ponikowski, Sanjiv J. Shah, M. Senni, O. Vedin, S. Verma, B. Peil, S. Pocock, F. Zannad, M. Packer, S. Anker   +19 more
semanticscholar   +1 more source

Heart Failure With Preserved Ejection Fraction [PDF]

Circulation, 2011
It is now well established that among patients with the clinical syndrome of heart failure (HF), approximately half have preserved systolic function, known most commonly as heart failure with preserved ejection fraction (HFpEF). Although originally considered to be predominantly a syndrome that pathophysiologically involves abnormalities in diastolic ...
openaire   +3 more sources

Novel pathways of heart failure with preserved ejection fraction [PDF]

, 2016
INTRODUCTION: Diastolic heart failure (HF) i.e., HF with preserved ejection fraction (HFpEF) accounts for ~50% of all clinical HF presentations; but unlike systolic HF i.e., HF with reduced ejection fraction (HFrEF), there are no evidenced based ...
Li, Shanpeng
core   +2 more sources

Hemodynamics and Kinetics of Heart Failure with Preserved Ejection Fraction Shock [PDF]

, 2022
The classical paradigm of cardiogenic shock is severe impairment of left ventricular, right ventricular, or biventricular contractility resulting in decreased cardiac output and end-organ failure. In patients with preserved ejection fraction, cardiogenic
Brailovsky, Yevgeniy, Le Jemtel, Thierry, Rajapreyar, Indranee, Rame, J. Eduardo   +3 more
core   +1 more source

Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction

European Heart Journal, 2021
Aims Patients with heart failure and preserved ejection fraction (HFpEF) frequently have difficult-to-control hypertension. We examined the effect of neprilysin inhibition on ‘apparent resistant hypertension’ in patients with HFpEF in the PARAGON-HF ...
A. Jackson, P. Jhund, I. Anand, H. Düngen, C. Lam, M. Lefkowitz, G. Linssen, L. Lund, A. Maggioni, M. Pfeffer, J. Rouleau, J. Saraiva, M. Senni, O. Vardeny, M. Wijkman, M. Yılmaz, Yoshihiko Saito, M. Zile, S. Solomon, J. McMurray   +19 more
semanticscholar   +1 more source

The Alberta Heart Failure Etiology and Analysis Research Team (HEART) study [PDF]

, 2014
Background Nationally, symptomatic heart failure affects 1.5-2% of Canadians, incurs $3 billion in hospital costs annually and the global burden is expected to double in the next 1–2 decades.
Anderson, Todd J., Becher, Harald, Belenkie, Israel, Clark, Alexander M., Duff, Henry J., Dyck, Jason R. B., Ezekowitz, Justin A., Fredrich, Matthias G., Haykowsky, Mark J., Howlett, Jonathan G., Kassiri, Zamaneh, Kaul, Padma, Kim, Daniel H., Knudtson, Merril L., Light, Peter E., Lopaschuk, Gary D., McAlister, Finlay A., Noga, Michelle L., Oudit, Gavin Y., Paterson, D. Ian, Quan, Hude, Schulz, Richard, Thompson, Richard B., Weeks, Sarah G.   +23 more
core   +1 more source

Current Treatment of Heart Failure with Preserved Ejection Fraction: Should We Add Life to the Remaining Years or Add Years to the Remaining Life?

Cardiology Research and Practice, 2013
According to the ejection fraction, patients with heart failure may be divided into two different groups: heart failure with preserved or reduced ejection fraction. In recent years, accumulating studies showed that increased mortality and morbidity rates
Jia Li, Peter Moritz Becher, Stefan Blankenberg, Dirk Westermann   +3 more
doaj   +1 more source